MP7 Aptamer Details
ID# 9105
Structure
Chemistry
DNA
Target
programmed cell death-1
Category
Protein
Affinity (Kd)
112 nM
Length
75
Aptazyme
No
Sequence (3-char table code)
G
A
C
U/T
dGpdApdCpdGpdApdTpdApdGpdCpdGpdGpdTpdGpdApdCpdGpdGpdTpdApdCpdApdGpdTpdTpdCpdCpdCpdGpdTpdCpdCpdCpdTpdGpdCpdApdCpdTpdApdCpdApdCpdGpdTpdApdTpdGpdCpdCpdGpdCpdTpdTpdCpdCpdGpdTpdCpdCpdGpdTpdCpdGpdCpdTpdCp
Molecular Weight: 22964.8 g/mole
Extinction Coefficient: 690200
Binding Conditions / Buffer
(10 mmol/l (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES), 150 mmol/l NaCl, 0.05% Tween-20, 1 mmol/l MgCl2, 1 mmol/l CaCl2)
Binding Temp: 37 °C°C
Refolding Protocol
If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Reference
Prodeus A, Abdul-Wahid A, Fischer NW, Huang EH, Cydzik M, Gariépy J. Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers. Mol Ther Nucleic Acids. 2015 Apr 28;4(4):e237. doi: 10.1038/mtna.2015.11. PMID: 25919090; PMCID: PMC4417124.
Request a Quote
Have your aptamer oligo synthesized by Aptagen.
